

Clinical Quality Measures
2023 measurement year

Measure		Rating	Rate
Adolescent Depression	PHQ-9 Utilization*	Below	46.70%
	Follow-up at Six Months	Expected	32.50%
	Response at Six Months	Expected	15.00%
	Remission at Six Months	Expected	10.00%
	Follow-up at 12 Months	Expected	25.00%
	Response at 12 Months	Expected	15.00%
	Remission at 12 Months	Expected	5.00%
Adult Depression	PHQ-9 Utilization*	Below	59.10%
	Follow-up at Six Months	Below Expected	30.10%
	Response at Six Months	Expected	16.90%
	Remission at Six Months	Expected	9.40%
	Follow-up at 12 Months	Below Expected	33.10%
	Response at 12 Months	Above Expected	27.40%
	Remission at 12 Months	Above Expected	21.40%
Adolescent Mental Health and/or Depression Screening*		Below	58.10%
Colorectal Cancer Screening		Below Expected	67.00%
Optimal Asthma Control - Adults		Below Expected	0.00%
Optimal Asthma Control - Children		Below Expected	0.90%
Optimal Diabetes Care		Expected	47.10%
HbA1c Control		Below Expected	71.00%
BP Control		Above Expected	87.50%
Daily Aspirin Use		Expected	99.00%
Statin Use		Above Expected	91.00%
Tobacco-Free		Below Expected	79.20%
Optimal Vascular Care		Expected	57.30%
BP Control		Above Expected	88.30%
Daily Aspirin Use		Above Expected	90.90%
Statin Use		Expected	90.60%
Tobacco-Free		Below Expected	75.20%

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

*Measure not risk adjusted

Healthcare Effectiveness Data and Information Set (HEDIS) Measures

2023 measurement year

Measure	Rating	Rate
Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis	Average	69.20%
Breast Cancer Screening	Above	82.90%
Cervical Cancer Screening	Average	75.90%
Childhood Immunization Status (Combo 10)	Below	37.50%
Chlamydia Screening in Women	Below	33.50%
Controlling High Blood Pressure	Average	73.30%
Diabetes Eye Exam	Average	63.50%
Immunizations for Adolescents (Combo 2)	Below	27.10%
Follow-up Care for Children Prescribed ADHD Medication	Average	30.90%
Osteoporosis Management in Women Who Had a Fracture	-	-
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Above	42.30%

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

Ratings

Above: Medical group's actual rate is significantly above its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Average: Medical group's actual rate is not statistically different than its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Below: Medical group's actual rate is significantly below its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Total Cost of Care

2023 measurement year

Population	Monthly Average Cost	Rating	Higher/Lower than Average
Overall	\$762	Higher than average	7.60%
Adults	\$911	Higher than average	9.60%
Pediatric	\$317	Average	-7.20%